CA2323896A1 - Crystalline form of paroxetine - Google Patents

Crystalline form of paroxetine Download PDF

Info

Publication number
CA2323896A1
CA2323896A1 CA002323896A CA2323896A CA2323896A1 CA 2323896 A1 CA2323896 A1 CA 2323896A1 CA 002323896 A CA002323896 A CA 002323896A CA 2323896 A CA2323896 A CA 2323896A CA 2323896 A1 CA2323896 A1 CA 2323896A1
Authority
CA
Canada
Prior art keywords
paroxetine
free base
crystalline
product
paroxetine free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323896A
Other languages
English (en)
French (fr)
Inventor
Andrew Simon Craig
Neal Ward
Wilson Mcilwaine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805581.7A external-priority patent/GB9805581D0/en
Priority claimed from GBGB9813054.5A external-priority patent/GB9813054D0/en
Priority claimed from GBGB9817115.0A external-priority patent/GB9817115D0/en
Application filed by Individual filed Critical Individual
Publication of CA2323896A1 publication Critical patent/CA2323896A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002323896A 1998-03-16 1999-03-16 Crystalline form of paroxetine Abandoned CA2323896A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9805581.7 1998-03-16
GBGB9805581.7A GB9805581D0 (en) 1998-03-16 1998-03-16 Novel compounds
GBGB9813054.5A GB9813054D0 (en) 1998-06-17 1998-06-17 Novel compounds
GB9813054.5 1998-06-17
GBGB9817115.0A GB9817115D0 (en) 1998-08-06 1998-08-06 Novel compounds
GB9817115.0 1998-08-06
PCT/GB1999/000793 WO1999047519A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Publications (1)

Publication Number Publication Date
CA2323896A1 true CA2323896A1 (en) 1999-09-23

Family

ID=27269245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323896A Abandoned CA2323896A1 (en) 1998-03-16 1999-03-16 Crystalline form of paroxetine

Country Status (18)

Country Link
EP (1) EP1064282A1 (ru)
JP (1) JP2002506865A (ru)
KR (1) KR20010041947A (ru)
CN (1) CN1300286A (ru)
AP (1) AP2000001907A0 (ru)
AU (1) AU2847199A (ru)
BG (1) BG104839A (ru)
BR (1) BR9908825A (ru)
CA (1) CA2323896A1 (ru)
EA (1) EA200000946A1 (ru)
HU (1) HUP0101215A3 (ru)
ID (1) ID27596A (ru)
IL (1) IL138390A0 (ru)
NO (1) NO20004583L (ru)
PL (1) PL342931A1 (ru)
SK (1) SK13622000A3 (ru)
TR (1) TR200002675T2 (ru)
WO (1) WO1999047519A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie

Also Published As

Publication number Publication date
ID27596A (id) 2001-04-12
EA200000946A1 (ru) 2001-02-26
HUP0101215A2 (hu) 2002-04-29
HUP0101215A3 (en) 2002-05-28
BG104839A (en) 2001-09-28
KR20010041947A (ko) 2001-05-25
AU2847199A (en) 1999-10-11
IL138390A0 (en) 2001-10-31
SK13622000A3 (sk) 2001-03-12
TR200002675T2 (tr) 2000-12-21
BR9908825A (pt) 2000-11-21
PL342931A1 (en) 2001-07-16
WO1999047519A1 (en) 1999-09-23
JP2002506865A (ja) 2002-03-05
CN1300286A (zh) 2001-06-20
NO20004583L (no) 2000-09-15
NO20004583D0 (no) 2000-09-14
EP1064282A1 (en) 2001-01-03
AP2000001907A0 (en) 2000-09-30

Similar Documents

Publication Publication Date Title
EP0808314B1 (en) Forms of paroxetin hydrochloride
EA025438B1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
US20150266860A1 (en) Crystalline form of a drug
US20060189675A1 (en) Crystalline form of a drug
EP1301508A1 (en) Novel processes for the preparation of 4-phenylpiperidine derivatives
WO2000035910A1 (en) Derivative of paroxetine
CA2323896A1 (en) Crystalline form of paroxetine
WO1994029303A1 (en) Heterocyclic chemistry
EP1135382A1 (en) Method of producing paroxetine hydrochloride
OA11635A (en) Process for the preparation of paroxetine hydrochloride.
MXPA00009137A (es) Forma cristalina de paroxetina
CZ20003343A3 (cs) Krystalická forma paroxetinu
EP1135383B1 (en) Mixed paroxetine propan-2-ol solvates
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
US20020137938A1 (en) Novel process
EP1242378A1 (en) Novel processes
WO2000032595A1 (en) Process for the production of paroxetine hydrochloride acetone solvate
EP1178962A1 (en) Process for the preparation of paroxetine acetate and analogues thereof
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
WO2000039121A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
EP1133492A1 (en) Process for the preparation of paroxetine hydrochloride
MXPA00006040A (en) Process for the preparation of paroxetine hydrochloride
WO2000032596A1 (en) Amine salts of paroxetine
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate

Legal Events

Date Code Title Description
FZDE Discontinued